RxDoctor Payments Data

July Gaysynsky, MD

Family Medicine · Valley Stream, NYNPI 1477731990

Payments from drug & device makers

$1,243in general payments, 2019–2025

Across 71 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$929
  • Novo Nordisk$211
  • AbbVie$70
  • Astellas Pharma US Inc$21
  • Lilly USA, LLC$12

What the payments were for

  • Food & beverage$1,23199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)56$929
Novo Nordisk10$211
AbbVie3$70
Astellas Pharma US Inc1$21
Lilly USA, LLC1$12

How this compares

$1,243 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$77,365
Medicare patients
129
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$144,188
Zileuton ErZileuton13$94,216
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate25$80,494
JardianceEmpagliflozin49$60,712
JanuviaSitagliptin Phosphate37$54,923
Diclofenac Sodium71$43,534
FarxigaDapagliflozin Propanediol36$42,022
TradjentaLinagliptin46$39,838
MounjaroTirzepatide31$39,583
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag15$39,168
JanumetSitagliptin Phos/Metformin Hcl24$32,619
EliquisApixaban21$30,267
EntrestoSacubitril/Valsartan16$16,823
WegovySemaglutide12$14,662
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$211$158,850148 claims
Lilly USA, LLCMounjaro$12$39,58331 claims
AbbVieLinzess, Synthroid$70$13,37261 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Valley Stream

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →